Supporting Information for

KA-11, a novel pyrrolidine-2,5-dione derived broad-spectrum anticonvulsant: its antiepileptogenic, antinociceptive properties and *in vitro* characterization

Katarzyna Socała,^{*,†} Szczepan Mogilski,[‡] Mateusz Pieróg,[†] Dorota Nieoczym,[†] Michał Abram,[§] Bartłomiej Szulczyk,^{∥,⊥} Annamaria Lubelska,[∇] Gniewomir Latacz,[∇] Urszula Doboszewska,[†] Piotr Wlaź,[†] and Krzysztof Kamiński[§]

[†]Department of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland. [‡]Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland. [§]Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland. [¶]Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. [¶]Department of Physiology and Pathophysiology, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland. [¶]Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.

Table of contents:

Figure S1. Effect of repeated pretreatment with KA-11 on the percentage of the open arms
entries and the percentage of the time spent in the open arms in the elevated plus maze test in
PTZ-kindled mice
Figure S2. Effect of repeated pretreatment with KA-11 on spontaneous locomotor activity in PTZ-kindled mice
Figure S3. Effect of acute pretreatment with KA-11 on motor coordination in the rotarod test
in miceS4




Figure S1. Effect of repeated pretreatment with **KA-11** on the percentage of the open arms entries (panel A) and the percentage of the time spent in the open arms (panel B) in the elevated plus maze test in PTZ-kindled mice. **KA-11** and VPA were injected *ip* once daily for 33 days. PTZ (40 mg/kg, *ip*) was injected every 48 h (in total 17 injections). Statistical analysis: one-way ANOVA. Data are expressed as means \pm SEM. n = 12-15 animals per group




Figure S2. Effect of repeated pretreatment with **KA-11** on spontaneous locomotor activity in PTZ-kindled mice. **KA-11** and VPA were injected *ip* once daily for 33 days. PTZ (40 mg/kg, *ip*) was injected every 48 h (in total 17 injections). Statistical analysis: one-way ANOVA. Data are expressed as means \pm SEM. n = 12-15 animals per group




Figure S3. Effect of acute pretreatment with **KA-11** on motor coordination in the rotarod test in mice. **KA-11** was injected *ip* 30 min before the test. Statistical analysis: one-way ANOVA. Data are expressed as means \pm SEM. n = 8-10 animals per group